

## Clinical Policy: Pegcetacoplan (Empaveli, Syfovre)

Reference Number: LA.PHAR.524

Effective Date: 05.10.24

Last Review Date: 12.11.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Pegcetacoplan (Empaveli<sup>®</sup>, Syfovre<sup>®</sup>) is a C3/C3b complement inhibitor.

### FDA Approved Indication(s)

Empaveli is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Syfovre is indicated for the treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections<sup>®</sup> that Empaveli and Syfovre are **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):

1. Diagnosis of PNH;
2. Request is for Empaveli;
3. Prescribed by or in consultation with a hematologist;
4. Age  $\geq$  18 years;
5. Flow cytometry shows detectable glycosylphosphatidylinositol (GPI)-deficient hematopoietic clones or  $\geq$  10% PNH cells;
6. Documentation of hemoglobin  $<$  10.5 g/dL;
7. Empaveli is not prescribed concurrently with either of the following (a and b):
  - a. Syfovre;
  - b. Another FDA-approved product for PNH (e.g., Soliris<sup>®</sup>, Ultomiris<sup>®</sup>, Fabhalta<sup>®</sup>, Voydeya<sup>™</sup>, Bkemb<sup>™</sup>), unless the member is in a 4-week period of cross-titration between Soliris/Bkemb and Empaveli;\*

*\*Provider must submit attestation of the presence or absence of concomitant Soliris/Bkemb therapy*

8. Dose does not exceed 2,160 mg per week or 1,080 mg every 3 days (total 10 doses per month) with documentation of a lactate dehydrogenase (LDH) level greater than 2 times the upper limit of normal (ULN).

**Approval duration: 6 weeks (if within cross-titration period with Soliris), or 6 months**

**B. Geographic Atrophy (must meet all):**

1. Diagnosis of GA secondary to AMD;
2. GA has all of the following characteristics confirmed on fundus autofluorescence imaging (a, b, c, and d):
  - a. Total GA area  $\geq 2.5$  and  $\leq 17.5$  mm<sup>2</sup> (1 and 7 disk areas [DA] respectively);
  - b. If GA is multifocal, at least one focal lesion  $\geq 1.25$  mm<sup>2</sup> (0.5 DA);
  - c. GA lesion(s) are not contiguous with any areas of peripapillary atrophy;
  - d. Presence of hyperautofluorescence in the junctional zone of GA;
3. Request is for Syfovre;
4. Prescribed by or in consultation with an ophthalmologist;
5. Age  $\geq 60$  years;
6. Best corrected visual acuity (BCVA) of 24 letters or better on Early Treatment Diabetic Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent);
7. Member does not have either of the following (a and b):
  - a. Diagnosis of any condition that may cause GA, including but not limited to pathologic myopia, Stargardt disease, cone rod dystrophy, and toxic maculopathies like Plaquenil maculopathy;
  - b. History of or active choroidal neovascularization (CNV) in the eye(s) affected by GA;
8. Syfovre is not prescribed concurrently with Empaveli;
9. Dose does not exceed 15 mg (0.1 mL of 150 mg/mL solution) in each affected eye every 25 days.

**Approval duration: 12 months**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255;
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):**

- a. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Request is for Empaveli;
3. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters (a – f):

- a. Improved measures of intravascular hemolysis (e.g., normalization of lactate dehydrogenase);
  - b. Reduced need for red blood cell transfusions;
  - c. Increased or stabilization of hemoglobin levels;
  - d. Less fatigue;
  - e. Improved health-related quality of life;
  - f. Fewer thrombotic events;
4. Empaveli is not prescribed concurrently with either of the following (a and b):
    - a. Syfovre;
    - b. Another FDA-approved product for PNH (e.g., Soliris, Ultomiris, Fabhalta, Voydeya, Bkemyv);
  5. If request is for a dose increase, new dose does not exceed 2,160 mg per week or 1,080 mg every 3 days (total 10 doses per month) with documentation of an LDH level greater than 2 times the ULN.

**Approval duration: 6 months**

**B. Geographic Atrophy (must meet all):**

1. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Request is for Syfovre;
3. Member is responding positively to therapy;
4. Syfovre is not prescribed concurrently with Empaveli;
5. If request is for a dose increase, new dose does not exceed 15 mg (0.1 mL of 150 mg/mL solution) in each affected eye every 25 days.

**Approval duration: 12 months**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one LA.PMN.255;
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AMD: age-related macular degeneration  
BCVA: best corrected visual acuity  
CNV: choroidal neovascularization  
DA: disk area

ETDRS: Early Treatment Diabetic  
Retinopathy Study  
FDA: Food and Drug Administration  
GA: geographic atrophy

GPI: glycosylphosphatidylinositol  
LDH: lactate dehydrogenase  
PNH: paroxysmal nocturnal hemoglobinuria

REMS: Risk Evaluation and Mitigation  
Strategy  
ULN: upper limit of normal

*Appendix B: Therapeutic Alternatives*  
Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s):
  - Empaveli: hypersensitivity to pegcetacoplan or any of the excipients; for initiation in patients with unresolved serious infection caused by encapsulated bacteria including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type B
  - Syfovre: ocular or periocular infections; active intraocular inflammation
- Boxed warning(s):
  - Empaveli: serious infections caused by encapsulated bacteria; Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)
  - Syfovre: none reported

## V. Dosage and Administration

| Drug Name | Indication | Dosing Regimen   | Maximum Dose  |
|-----------|------------|--|---------------|
| Empaveli  | PNH        | <p>1,080 mg SC twice weekly via a commercially available infusion pump or the Empaveli on body injector</p> <p>For patients switching from Soliris/Bkemv, initiate Empaveli while continuing Soliris/Bkemv at its current dose. After 4 weeks, discontinue Soliris/Bkemv before continuing on monotherapy with Empaveli.</p> <p>For patients switching from Ultomiris, initiate Empaveli no more than 4 weeks after the last dose of Ultomiris.</p> <p>For LDH levels &gt; 2x ULN, adjust the dosing regimen to 1,080 mg every three days.</p> | 1,080 mg/dose |
| Syfovre   | GA         | 15 mg (0.1 mL of 150 mg/mL solution) via intravitreal injection to each affected eye once every 25 to 60 days  | 15 mg/25 days |

## VI. Product Availability

| Drug Name | Availability  |
|-----------|---|
| Empaveli  | Single-dose vial for subcutaneous injection: 1,080 mg/20 mL |

| Drug Name | Availability   |
|-----------|--|
| Syfovre   | Single-dose vial for intravitreal injection: 150 mg/mL |

## VII. References

1. Empaveli Prescribing Information. Waltham, MA: Apellis Pharmaceuticals, Inc.; February 2024. Available at: <https://empavelihcp.com/>. Accessed May 8, 2024.
2. Wong R, Pullon H, Deschatelets P, et al. Inhibition of C3 with APL-2 results in normalization of markers of intravascular and extravascular hemolysis in subjects with paroxysmal nocturnal hemoglobinuria (PNH). Poster presented at: American Society of Hematology (ASH). 2018.
3. Hillmen P, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *NEJM* March 2021;384:1028-37.
4. Bhak RY, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Abstract 2581. Presented at the 62<sup>nd</sup> American Society of Hematology Annual Meeting and Exposition, Dec 2-11, 2020.
5. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Blood* 2005; 106(12):3699-3709. Doi:10.1182/blood-2005-04-1717.
6. Apellis Pharmaceuticals, Inc. Study of pegcetacoplan (APL-2) therapy in patients with geographic atrophy (FILLY). ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT02503332>. Accessed May 15, 2024.
7. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: A randomized phase 2 trial. *Ophthalmology*. 2020; 127(2): 186-195.
8. Apellis Pharmaceuticals, Inc. Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (DERBY). ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT03525600>. Accessed May 15, 2024.
9. Apellis Pharmaceuticals, Inc. A study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (OAKS). ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT03525613>. Accessed May 15, 2024.
10. Goldberg R, Heier JS, Wyoff CC, et al. Abstract: Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. *Investigative Ophthalmology & Visual Science*. 2022; 63(7): 1500.
11. Apellis Pharmaceuticals, Inc. Apellis announces pegcetacoplan showed continuous and clinically meaningful effects at month 18 in phase 3 DERBY and OAKS studies for geographic atrophy (GA). News release published March 16, 2022. Available at: <https://investors.apellis.com/news-releases/news-release-details/apellis-announces-pegcetacoplan-showed-continuous-and-clinically>. Accessed May 15, 2024.
12. American Academy of Ophthalmology Retina/Vitreous Committee. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>. Accessed May 15, 2024.
13. Syfovre Prescribing Information. Waltham, MA: Apellis Pharmaceuticals, Inc.; November 2023. Available at: <https://syfovre.com>. Accessed May 8, 2024.

14. Regillo CD, Nijm LM, Shechtman DL, et al. Considerations for the identification and management of geographic atrophy: Recommendations from an expert panel. *Clinical Ophthalmology*. 2024; 18: 325-335.

### **Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| <b>HCPCS Codes</b> | <b>Description</b>   |
|--------------------|--|
| J2781              | Injection, pegcetacoplan, intravitreal, 1 mg                     |
| J7799              | Noc drugs, other than inhalation drugs, administered through dme |

| <b>Reviews, Revisions, and Approvals</b>   | <b>Date</b> | <b>LDH Approval Date</b> |
|--|-------------|--------------------------|
| Converted corporate to local policy.   | 04.04.24    | 05.10.24                 |
| For PNH, added Fabhalta, Voydeya, and Bkemb to the list of therapies that Empaveli should not be prescribed concurrently with; for GA, clarified that diagnostic characteristics must be confirmed on fundus autofluorescence imaging per health plan request and in alignment with pivotal study design; revised Empaveli contraindications in Appendix C per updated prescribing information; references reviewed and updated. | 12.11.24    |                          |

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.



This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.